I think he has learned from his past when it comes to describing the potential for ANAVEX and it's products and applications for a myriad of diseases. I'm fine with him downplaying it.
His choice of words (or his attorney's choice) is what I expect especially considering the pending securities litigation. Therefore, I am not bothered by this language, which is to be expected considering the circumstances. I am sure that all PR statements are reviewed by an attorney, and attorneys will err in favor of toning down statements by Anavex.
News 
Market Data 
Discover 
